Direct line: 1300 987 995
Jan 28 (Reuters) - ARIAD Pharmaceuticals Inc
* Announces commercial agreement for iclusig (ponatinib) in Australia
* Granted sta exclusive rights to commercialize iclusig in Australia in
patients with Philadelphia-positive leukemias
* Says term of the agreement is seven years from the first commercial sale of
iclusig following reimbursement approval
* After the term, co will have option to take over commercialization of iclusig
in Australia or to extend the agreement with sta
* Says commercial launch of iclusig are expected in the fourth quarter of 2014
* As per terms,sta will book sales of iclusig to pharmacies and other
distributors, while Ariad will supply packaged drug to sta
* At conclusion of term, co may take over the commercialization or extend deal
with specialised therapeutics Australia pty ltd
* Source text for Eikon
* Further company coverage
((Bangalore Newsroom; +1 646 223 8780))